Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for rare liver diseases. The company's lead product, LIVMARLI (maralixibat), is an orally administered inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).

The company is also developing LIVMARLI for other rare cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. In addition to LIVMARLI, Mirum has a pipeline of other product candidates for rare liver diseases, including volixibat, another ASBT inhibitor, for the treatment of primary sclerosing cholangitis and primary biliary cholangitis.

Mirum's business model is focused on developing and commercializing its product candidates in the United States and other major markets. The company has a commercial team in place in the United States and is building a commercial infrastructure in other countries. Mirum's target clients are patients with rare liver diseases, and the company works with physicians, payers, and patient advocacy groups to ensure that patients have access to its products.

Keywords: biopharmaceutical, rare liver diseases, cholestatic pruritus, Alagille syndrome, LIVMARLI, maralixibat, volixibat, ASBT inhibitor, orphan drugs, pediatric hepatology